Evidence map›Paper›PMID 27535048›Full record

ArticleJournal of virology2016

Stimulation of the Replication of ICP0-Null Mutant Herpes Simplex Virus 1 and pp71-Deficient Human Cytomegalovirus by Epstein-Barr Virus Tegument Protein BNRF1.

Yongxu Lu, Anne Orr, Roger D Everett

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Sp140L functions as a herpesvirus restriction factor suppressing viral transcription and activating interferon-stimulated genes.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. The Fate of Speckled Protein 100 (Sp100) During Herpesviruses Infection.Frontiers in cellular and infection microbiology · 2020
    Review
  8. USP7: Novel Drug Target in Cancer Therapy.Frontiers in pharmacology · 2019
    Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yongxu LuMRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdom.
Anne OrrMRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdom.
Roger D EverettMRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdom roger.everett@glasgow.ac.uk.
MRC University of Glasgow Centre for Virus Research · GB

Funding

Medical Research Council MC_UU_12014/4
6 · The paper itself

Abstract

It is now well established that several cellular proteins that are components of promyelocytic leukemia nuclear bodies (PML NBs, also known as ND10) have restrictive effects on herpesvirus infections that are countered by viral proteins that are either present in the virion particle or are expressed during the earliest stages of infection. For example, herpes simplex virus 1 (HSV-1) immediate early (IE) protein ICP0 overcomes the restrictive effects of PML-NB components PML, Sp100, hDaxx, and ATRX while human cytomegalovirus (HCMV) IE protein IE1 targets PML and Sp100, and its tegument protein pp71 targets hDaxx and ATRX. The functions of these viral regulatory proteins are in part interchangeable; thus, both IE1 and pp71 stimulate the replication of ICP0-null mutant HSV-1, while ICP0 increases plaque formation by pp71-deficient HCMV. Here, we extend these studies by examining proteins that are expressed by Epstein-Barr virus (EBV). We report that EBV tegument protein BNRF1, discovered by other investigators to target the hDaxx/ATRX complex, increases the replication of both ICP0-null mutant HSV-1 and pp71-deficient HCMV. In addition, EBV protein EBNA-LP, which targets Sp100, also augments ICP0-null mutant HSV-1 replication. The combination of these two EBV regulatory proteins had a greater effect than each one individually. These findings reinforce the concept that disruption of the functions of PML-NB proteins is important for efficient herpesvirus infections. IMPORTANCE: Whether a herpesvirus initiates a lytic infection in a host cell or establishes quiescence or latency is influenced by events that occur soon after the viral genome has entered the host cell nucleus. Certain cellular proteins respond in a restrictive manner to the invading pathogen's DNA, while viral functions are expressed that counteract the cell-mediated repression. One aspect of cellular restriction of herpesvirus infections is mediated by components of nuclear structures known as PML nuclear bodies (PML NBs), or ND10. Members of the alpha-, beta-, and gammaherpesvirus families all express proteins that interact with, degrade, or otherwise counteract the inhibitory effects of various PML NB components. Previous work has shown that there is the potential for a functional interchange between the viral proteins expressed by alpha- and betaherpesviruses, despite a lack of obvious sequence similarity. Here, this concept is extended to include a member of the gammaherpesviruses.

Indexed as

Adaptor Proteins, Signal TransducingAntigens, NuclearAutoantigensCell LineCo-Repressor ProteinsCytomegalovirusCytomegalovirus InfectionsDNA HelicasesDNA ReplicationGene Expression Regulation, ViralHerpes SimplexHerpesviridae InfectionsHerpesvirus 1, HumanHerpesvirus 4, HumanHumansImmediate-Early ProteinsAdaptor Proteins, Signal TransducingAntigens, NuclearATRX protein, humanAutoantigensCo-Repressor ProteinsDAXX protein, humanDNA HelicasesEBNA-LP protein, Human herpesvirus 4gene 63 protein, Equine herpesvirus 1IE1 protein, cytomegalovirusImmediate-Early ProteinsMolecular ChaperonesNuclear ProteinsP140 protein, Epstein-barr virusPromyelocytic Leukemia ProteinSP100 protein, humanTranscription FactorsViral Envelope ProteinsViral ProteinsX-linked Nuclear Protein

Identifiers

PMID27535048
PMCPMC5068519
OpenAlexW2508639720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.